# Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)

> **NCT00424385** · PHASE1 · COMPLETED · sponsor: **Oncology Specialists, S.C.** · enrollment: 17 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Gleevec + Sorafenib

## Key facts

- **NCT ID:** NCT00424385
- **Lead sponsor:** Oncology Specialists, S.C.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2014-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00424385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00424385, "Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00424385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*